Lumito (LUMITO) investor relations material

Technology and product

• Proprietary technology captures low-abundance tissue biomarkers; sensitivity is 15x conventional chromogenic HRP DAB and 9x or more high-sensitivity methods.

• In four breast cancer samples assessed as HER2-negative, the solution detected and measured HER2 in three.

• Product offering includes a reagent kit and Whole Slide Image Scanner, supporting recurring and non-recurring revenue from reagents, instruments, and services.

Commercial traction and scaling

• First paying customers and repeat orders in the Nordics and outside the region; sales include Scan-as-a-Service and reagent kits, with early pharma engagement.

• CRO partnerships are expanding rapidly; direct customer engagement also targets academic, research, and pharma customers.

Evidence and operational foundation

• Research-use product is CE marked, with production agreements from stable suppliers and a fit-for-purpose quality management system.

• Pilot evaluations and technology integration projects with academic and clinical researchers and other field participants are building a larger evidence base.

• Scientific, clinical, research, business development, and commercial advisors provide expertise and introductions to potential partners and key players.